vs
AGENUS INC（AGEN）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
REPLIGEN CORP的季度营收约是AGENUS INC的5.8倍（$197.9M vs $34.2M）。REPLIGEN CORP净利率更高（6.7% vs -31.0%，领先37.7%）。AGENUS INC同比增速更快（27.5% vs 13.6%）。过去两年REPLIGEN CORP的营收复合增速更高（14.4% vs 10.5%）
Agenus Inc.是一家总部位于美国马萨诸塞州列克星敦的生物技术公司，核心业务聚焦免疫治疗领域，尤其专注于利用人体免疫系统控制或治愈癌症的肿瘤免疫治疗。公司目前正在研发检查点调节剂、个性化抗癌疫苗，以及可适配多种疫苗的免疫佐剂，其中检查点调节剂作为当前进展迅速的方向，早期产品已为患者带来突破性临床获益。
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
AGEN vs RGEN — 直观对比
营收规模更大
RGEN
是对方的5.8倍
$34.2M
营收增速更快
AGEN
高出13.8%
13.6%
净利率更高
RGEN
高出37.7%
-31.0%
两年增速更快
RGEN
近两年复合增速
10.5%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $34.2M | $197.9M |
| 净利润 | $-10.6M | $13.3M |
| 毛利率 | — | 52.5% |
| 营业利润率 | 42.1% | 9.0% |
| 净利率 | -31.0% | 6.7% |
| 营收同比 | 27.5% | 13.6% |
| 净利润同比 | 77.3% | 143.9% |
| 每股收益（稀释后） | $0.09 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AGENRGEN
| Q4 25 | $34.2M | $197.9M | ||
| Q3 25 | $30.2M | $188.8M | ||
| Q2 25 | $25.7M | $182.4M | ||
| Q1 25 | $24.1M | $169.2M | ||
| Q4 24 | $26.8M | $174.1M | ||
| Q3 24 | $25.1M | $154.9M | ||
| Q2 24 | $23.5M | $154.1M | ||
| Q1 24 | $28.0M | $151.3M |
净利润AGENRGEN
| Q4 25 | $-10.6M | $13.3M | ||
| Q3 25 | $63.9M | $14.9M | ||
| Q2 25 | $-30.0M | $14.9M | ||
| Q1 25 | $-26.4M | $5.8M | ||
| Q4 24 | $-46.8M | $-30.3M | ||
| Q3 24 | $-67.2M | $-654.0K | ||
| Q2 24 | $-54.8M | $3.3M | ||
| Q1 24 | $-63.5M | $2.1M |
毛利率AGENRGEN
| Q4 25 | — | 52.5% | ||
| Q3 25 | 97.9% | 53.2% | ||
| Q2 25 | 99.1% | 50.0% | ||
| Q1 25 | 99.4% | 53.6% | ||
| Q4 24 | 99.6% | 26.1% | ||
| Q3 24 | 99.4% | 50.0% | ||
| Q2 24 | 99.5% | 49.8% | ||
| Q1 24 | 99.6% | 49.5% |
营业利润率AGENRGEN
| Q4 25 | 42.1% | 9.0% | ||
| Q3 25 | -15.0% | 8.9% | ||
| Q2 25 | -65.0% | 7.6% | ||
| Q1 25 | -55.3% | 3.9% | ||
| Q4 24 | -96.5% | -17.7% | ||
| Q3 24 | -125.5% | -5.1% | ||
| Q2 24 | -128.4% | 1.0% | ||
| Q1 24 | -117.4% | 1.3% |
净利率AGENRGEN
| Q4 25 | -31.0% | 6.7% | ||
| Q3 25 | 211.4% | 7.9% | ||
| Q2 25 | -116.8% | 8.2% | ||
| Q1 25 | -109.6% | 3.4% | ||
| Q4 24 | -174.4% | -17.4% | ||
| Q3 24 | -267.7% | -0.4% | ||
| Q2 24 | -233.1% | 2.2% | ||
| Q1 24 | -226.6% | 1.4% |
每股收益（稀释后）AGENRGEN
| Q4 25 | $0.09 | $0.24 | ||
| Q3 25 | $1.94 | $0.26 | ||
| Q2 25 | $-1.00 | $0.26 | ||
| Q1 25 | $-1.03 | $0.10 | ||
| Q4 24 | $-1.95 | $-0.55 | ||
| Q3 24 | $-3.08 | $-0.01 | ||
| Q2 24 | $-2.52 | $0.06 | ||
| Q1 24 | $-3.04 | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.0M | $767.6M |
| 总债务越低越好 | $44.7M | $542.2M |
| 股东权益账面价值 | $-271.1M | $2.1B |
| 总资产 | $226.8M | $2.9B |
| 负债/权益比越低杠杆越低 | — | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资AGENRGEN
| Q4 25 | $3.0M | $767.6M | ||
| Q3 25 | $3.5M | $748.7M | ||
| Q2 25 | $9.5M | $708.9M | ||
| Q1 25 | $18.5M | $697.2M | ||
| Q4 24 | $40.4M | $757.4M | ||
| Q3 24 | $44.8M | $784.0M | ||
| Q2 24 | $93.7M | $809.1M | ||
| Q1 24 | $52.9M | $780.6M |
总债务AGENRGEN
| Q4 25 | $44.7M | $542.2M | ||
| Q3 25 | $34.2M | $537.9M | ||
| Q2 25 | $33.9M | — | ||
| Q1 25 | $33.6M | — | ||
| Q4 24 | $33.2M | $525.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益AGENRGEN
| Q4 25 | $-271.1M | $2.1B | ||
| Q3 25 | $-274.1M | $2.1B | ||
| Q2 25 | $-354.6M | $2.1B | ||
| Q1 25 | $-341.8M | $2.0B | ||
| Q4 24 | $-326.4M | $2.0B | ||
| Q3 24 | $-292.3M | $2.0B | ||
| Q2 24 | $-241.3M | $2.0B | ||
| Q1 24 | $-201.4M | $2.0B |
总资产AGENRGEN
| Q4 25 | $226.8M | $2.9B | ||
| Q3 25 | $233.9M | $2.9B | ||
| Q2 25 | $185.2M | $2.9B | ||
| Q1 25 | $200.2M | $2.9B | ||
| Q4 24 | $226.3M | $2.8B | ||
| Q3 24 | $238.5M | $2.8B | ||
| Q2 24 | $292.4M | $2.9B | ||
| Q1 24 | $256.6M | $2.8B |
负债/权益比AGENRGEN
| Q4 25 | — | 0.26× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.27× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-16.6M | $25.7M |
| 自由现金流经营现金流 - 资本支出 | — | $17.6M |
| 自由现金流率自由现金流/营收 | — | 8.9% |
| 资本支出强度资本支出/营收 | 0.0% | 4.1% |
| 现金转化率经营现金流/净利润 | — | 1.93× |
| 过去12个月自由现金流最近4个季度 | — | $93.9M |
8季度趋势，按日历期对齐
经营现金流AGENRGEN
| Q4 25 | $-16.6M | $25.7M | ||
| Q3 25 | $-14.7M | $48.1M | ||
| Q2 25 | $-20.2M | $28.6M | ||
| Q1 25 | $-25.6M | $15.0M | ||
| Q4 24 | $-28.7M | $39.2M | ||
| Q3 24 | $-53.3M | $49.3M | ||
| Q2 24 | $-38.2M | $42.2M | ||
| Q1 24 | $-38.2M | $44.7M |
自由现金流AGENRGEN
| Q4 25 | — | $17.6M | ||
| Q3 25 | — | $43.4M | ||
| Q2 25 | $-20.2M | $21.5M | ||
| Q1 25 | $-25.6M | $11.4M | ||
| Q4 24 | $-28.7M | $33.6M | ||
| Q3 24 | $-53.3M | $42.3M | ||
| Q2 24 | $-38.6M | $37.4M | ||
| Q1 24 | $-38.2M | $36.4M |
自由现金流率AGENRGEN
| Q4 25 | — | 8.9% | ||
| Q3 25 | — | 23.0% | ||
| Q2 25 | -78.7% | 11.8% | ||
| Q1 25 | -106.5% | 6.8% | ||
| Q4 24 | -107.0% | 19.3% | ||
| Q3 24 | -212.2% | 27.3% | ||
| Q2 24 | -164.4% | 24.3% | ||
| Q1 24 | -136.5% | 24.0% |
资本支出强度AGENRGEN
| Q4 25 | 0.0% | 4.1% | ||
| Q3 25 | 0.0% | 2.5% | ||
| Q2 25 | 0.0% | 3.9% | ||
| Q1 25 | 0.0% | 2.1% | ||
| Q4 24 | 0.3% | 3.2% | ||
| Q3 24 | 0.0% | 4.5% | ||
| Q2 24 | 2.0% | 3.1% | ||
| Q1 24 | 0.1% | 5.5% |
现金转化率AGENRGEN
| Q4 25 | — | 1.93× | ||
| Q3 25 | -0.23× | 3.23× | ||
| Q2 25 | — | 1.92× | ||
| Q1 25 | — | 2.57× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 12.70× | ||
| Q1 24 | — | 21.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
